Welcome to the resource library, where you can find strategy, research and examples of promising practice in medicine, commissioning and drug services for hepatitis C
Resources
Showing 1 to 10 of 21 resources
-
Global Hepatitis Report 2017
This WHO Global hepatitis report describes the global and regional estimates on viral hepatitis in 2015, setting the baseline for tracking progress in implementing the new global strategy.Rest of World Apr 2017 Reports & Research PDF -
Guidelines on hepatitis B and C testing
These are the first WHO guidelines on testing for chronic hepatitis B and C infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for hepatitis B and C, and are intended for use across age groups and populations.Rest of World Feb 2017 Other, Strategy & Planning PDF -
The 2016 Hep-CORE Report: Monitoring the implementation of hepatitis B and C policy recommendations in Europe
Published by the European Liver Patients Association, this report provides an overview of the progress made in tackling hepatitis B and C across different European countries, on the basis of surveys undertaken with patient organisations.Rest of World Jan 2017 Reports & Research PDF -
Drug-related infectious diseases in Europe
This report provides an update on infectious diseases related to drug use in Europe for the period up to June 2016. It covers the most recent data both on infectious diseases among people who inject drugs in Europe, collected with the European Monitoring Centre for Drugs and Drug Addiction Drug-related infectious diseases (DRID) indicator, and on the responses in the area. It includes highlights and new findings discussed during the DRID indicator’s annual expert meeting, held in Lisbon on 6–8 June 2016.Rest of World Reports & Research PDF -
Global report on access to hepatitis C treatment - Focus on overcoming barriers
This is the first-ever global report on treatment access to hepatitis C medicines. The report provides the information that countries and health authorities need to identify the appropriate HCV treatment, and procure it at affordable prices. The report uses the experience of several pioneering countries to demonstrate how barriers to treatment access can be overcome.Rest of World Oct 2016 Reports & Research PDF -
EASL Recommendations on Treatment of Hepatitis C 2016
These EASL Recommendations on Treatment of Hepatitis C are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decision-making process by describing the current optimal management of patients with acute and chronic HCV infections. These recommendations apply to therapies that have been approved by the European Medicines Agency and other national European agencies at the time of their publication.Rest of World Sep 2016 Other, Reports & Research PDF -
Extrahepatic manifestations of chronic hepatitis C infection
This research article provides an overview of the extrahepatic (i.e. non-liver) impact of hepatitis C, which include cardiovascular, renal, metabolic and central nervous system diseases.UK, Rest of World Aug 2016 Reports & Research PDF -
Hepatitis C among drug users in Europe: Epidemiology, treatment and prevention
This report, produced by the European Monitoring Centre for Drugs and Drug Addiction, provides an overview of the epidemiology of hepatitis C in Europe. It contains chapters on issues such as providing hepatitis C treatment to people who inject drugs, strategies to improve hepatitis C care and increasing uptake of treatment among people who inject drugs, and hepatitis C prevention among people who inject drugs.UK, Rest of World Aug 2016 Reports & Research, Strategy & Planning PDF -
WHO Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection
These guidelines, developed by the World Health Organisation, promote the transition to newer, more effective medicines that have the potential to cure most persons living with hepatitis C infection. They also provide guidance on which specific regimens should be used based on a patient’s clinical history as well as genotype, and are intended to promote the scale-up of hepatitis C treatment.UK, Rest of World Apr 2016 Other, Strategy & Planning PDF -
Vertical transmission of hepatitis C: towards universal antenatal screening in the era of new direct acting antivirals (DAAs)? Short review and analysis of the situation in Switzerland
This article uses the example of Switzerland to look at how recent developments in hepatitis C therapy might impact upon the prevention of hepatitis C vertical (i.e. mother to baby) transmission. It finds that universal screening for hepatitis C among pregnant women should be urgently re-evaluated in the light of the new treatments which are now available.Rest of World Feb 2016 Reports & Research PDF